- Home
- LPAA vs CTMX Comparison
LPAA vs CTMX Comparison
Compare LPAA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPAA
- CTMX
- Stock Information
- Founded
- LPAA 2024
- CTMX 2008
- Country
- LPAA United States
- CTMX United States
- Employees
- LPAA N/A
- CTMX N/A
- Industry
- LPAA
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- LPAA
- CTMX Health Care
- Exchange
- LPAA Nasdaq
- CTMX Nasdaq
- Market Cap
- LPAA 299.3M
- CTMX 349.6M
- IPO Year
- LPAA 2024
- CTMX 2015
- Fundamental
- Price
- LPAA $10.47
- CTMX $2.28
- Analyst Decision
- LPAA
- CTMX Strong Buy
- Analyst Count
- LPAA 0
- CTMX 3
- Target Price
- LPAA N/A
- CTMX $5.67
- AVG Volume (30 Days)
- LPAA 13.8K
- CTMX 4.1M
- Earning Date
- LPAA 01-01-0001
- CTMX 11-06-2025
- Dividend Yield
- LPAA N/A
- CTMX N/A
- EPS Growth
- LPAA N/A
- CTMX 263.20
- EPS
- LPAA 0.35
- CTMX 0.49
- Revenue
- LPAA N/A
- CTMX $141,100,000.00
- Revenue This Year
- LPAA N/A
- CTMX N/A
- Revenue Next Year
- LPAA N/A
- CTMX N/A
- P/E Ratio
- LPAA $29.73
- CTMX $4.66
- Revenue Growth
- LPAA N/A
- CTMX 18.01
- 52 Week Low
- LPAA $9.96
- CTMX $0.40
- 52 Week High
- LPAA $10.70
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- LPAA 61.29
- CTMX 57.29
- Support Level
- LPAA $10.43
- CTMX $2.02
- Resistance Level
- LPAA $10.45
- CTMX $2.17
- Average True Range (ATR)
- LPAA 0.01
- CTMX 0.15
- MACD
- LPAA 0.00
- CTMX 0.03
- Stochastic Oscillator
- LPAA 77.41
- CTMX 97.53
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.